Neutrophil-to-lymphocyte ratio as a prognostic factor in patients during palliative treatment of pancreatic ductal adenocarcinoma with a FOLFIRINOX regimen

Introduction. Difficulties in advanced pancreatic ductal adenocarcinoma (PDAC) treatment require a constant search for novel prognostic factors. The aim of this study is to determine the role various morphological parameters pre­dicting prognosis PDAC during systemic therapy with FOLFIRINOX regimen. Material and methods. data 52 patients, treated chemotherapy due metastatic were analyzed retrospectively study. Results. median time overall survival (OS) group patients neutrophil-to-lymphocyte ratio (NLR) ≥3 was 5.8 months, compared 14.5 months NLR < 3. Median progression-free (PFS) ≥ 3 4.1 8.5 There no statistically significant differences among concerning lymphocyte-to-monocyte (LMR) platelets-to-lymphocyte (PLR). Conclusions. Higher negative factor PDAC.